Archive for the ‘Gene Therapy Research’ Category

Let #39;s Play The Sims 3 - Perfect Genetics Challenge - Episode 4 - The First Born
Life moves fast in Riverview for Stefan and Heather. A new addition to the house in anticipation of their first child finds new purposes before being handed ...

By: Llandros09

Originally posted here:
Let's Play The Sims 3 - Perfect Genetics Challenge - Episode 4 - The First Born - Video

RUTHERFORD, N.J.--(BUSINESS WIRE)--

Cancer Genetics, Inc. (CGIX) ("CGI" or the "Company"), a leader in oncology-focused personalized medicine, will hold a conference call on Thursday, May 16, 2013, at 9:00 a.m. Eastern time to discuss its results for the first quarter ended March 31, 2013.

Cancer Genetics president and chief executive officer, Panna Sharma, and chief financial officer, Elizabeth Czerepak, will host the call and be available during the question-and-answer session.

To participate in the call, please dial (877) 941-1428, or (480) 629-9665 for international calls, approximately 10 minutes prior to the scheduled start time. Interested parties can also listen via a live Internet webcast, which can be found via the Companys website at http://ir.stockpr.com/cancergenetics/events, or alternately at http://ViaVid.net.

A replay of the call will be available for two weeks from 5:00 p.m. ET on May 16, 2013, until 11:59 p.m. ET on May 30, 2013. The number for the replay is (877) 870-5176, or (858) 384-5517 for international calls; the passcode for the replay is 4619856. In addition, a recording of the call will be available via the Companys website at http://www.cancergenetics.com.

About Cancer Genetics, Inc.

Cancer Genetics, Inc. (CGI) is an emerging leader in DNA-based cancer diagnostics and servicessome of the most prestigious medical institutions in the world. Our tests target cancers that are difficult to diagnose and predict treatment outcomes. These cancers include hematological, urogenital and HPV-associated cancers. We also provide a comprehensive range of non-proprietary oncology-focused tests and laboratory services.

CGIs cutting-edge proprietary tests and state-of-the-art reference laboratory provide critical genomic information to healthcare professionals as well as biopharma and biotech. Our state-of-the-art reference lab is focused entirely on maintaining clinical excellence and is both CLIA certified and CAP accredited and has licensure from several states including New York State.

Founded in 1999 by world-renowned cytogeneticist Dr. R.S.K. Chaganti, the Company has been built on a foundation of world-class scientific knowledge and IP in solid and blood-borne cancers, and has established strong research collaborations with major cancer centers such as Memorial Sloan-Kettering, The Cleveland Clinic and the National Cancer Institute. For further information, please seewww.cancergenetics.com.

More here:
Cancer Genetics Announces Conference Call to Discuss First Quarter Results

Stem Cell Therapy for Knees, Osteoarthritis and Autoimmune Disorders: King Goff Discusses Treatment
King Goff received three applications of his own adipose tissue-derived stem cells over the course of 3 days for a knee injury and autoimmune issues at the S...

By: cellmedicine

Read this article:
Stem Cell Therapy for Knees, Osteoarthritis and Autoimmune Disorders: King Goff Discusses Treatment - Video

Bharat Book Presents: Cell Therapy Technologies, Markets and Companies
For More Information Kindly Visit On : http://www.bharatbook.com/market-research-reports/healthcare-market-research-report/cell-therapy-technologies-markets-and-companies.html Summary This...

By: Deepa Kamath

Read more:
Bharat Book Presents: Cell Therapy Technologies, Markets and Companies - Video

DUBLIN--(BUSINESS WIRE)--

Research and Markets (http://www.researchandmarkets.com/research/bvsbx5/cell_therapy) has announced the addition of the "Cell Therapy Partnering Yearbook 2013" report to their offering.

The Cell Therapy Partnering Yearbook 2013 report series provides comprehensive understanding and unprecedented access to the partnering deals and agreements entered into by the worlds leading healthcare companies during 2012.

Using these reports, dealmakers will effectively and efficiently gain insight into the partnering activities of the past year. The report series allows you to view all the partnering and alliances deals announced worldwide.

The initial chapters of this report provide an orientation of 2012's dealmaking and business activities.

The chapter is organized by company A-Z, stage of development at signing, deal type (collaborative R&D, co-promotion, licensing etc), therapy area and technology type. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.

The report series also includes numerous tables and figures that illustrate the trends and activities in bigpharma partnering and dealmaking during 2012.

In conclusion, this report provides everything a prospective dealmaker needs to know about partnering in the research, development and commercialization of technologies and products during 2012.

Key benefits

- In-depth understanding of recent dealmaking trends during 2012

Read more from the original source:
Research and Markets: Cell Therapy Partnering Yearbook 2013

STOCKHOLM, Sweden--(BUSINESS WIRE)--

Regulatory News:

Elekta (NSE:EKTAB.ST) and Royal Philips Electronics (NYSE: PHG, AEX: PHIA) announced today that Sunnybrook Health Sciences Centre (Toronto, Canada) will join their growing consortium to validate the clinical potential of MRI-guided radiation therapy.

Sunnybrook Health Sciences Centre, the sixth largest cancer center in North America, is the fourth member to sign the research agreement to evaluate the new technology, which merges radiation therapy and magnetic resonance imaging (MRI) in a single system. Current clinical members of the group include the University Medical Center Utrecht, The University of Texas MD Anderson Cancer Center, and The Netherlands Cancer Institute-Antoni van Leeuwenhoek Hospital.

Integrating an advanced 1.5 Tesla MRI machine with a sophisticated radiation therapy system will provide physicians with exceptional depictions of a patients soft tissues and tumor and allow them to dynamically track their motion. This breakthrough innovation is designed to permit doctors to deliver radiation in real time under MR guidance for the most precise cancer treatments possible.

Sunnybrook Health Sciences Centre distinguishes itself in the world of science and medicine by its longstanding dedication of integrating research into clinical domain for the benefit of patients, says Tomas Puusepp, Elekta President and CEO. With their international strength in the physical sciences particularly in imaging technology and its worldwide repute as a top flight cancer center, Sunnybrook is an ideal partner to help us advance this new technology.

According to Michael Julius, Vice President, Research at Sunnybrook Health Sciences Centre, Sunnybrooks participation in the research consortium will bring a unique team of physicists, engineers and clinicians to focus on validating the advantages of MRI-guided radiation therapy through technology development and clinical trials.

We have identified a number of areas to study the value of this technology for patients, he says. The ultimate goal acquiring high resolution MRI images of pathology in real time as the radiation is being delivered could have a dramatic impact on patient health and clinical outcomes.

Today, the safety margin of normal tissue around the tumor absorbs a large portion of the radiation beam, adds Jean-Philippe Pignol, Professor of Radiation Oncology and a key leader on the Elekta partnership at Sunnybrooks Odette Cancer Centre. The expectation is that MR-guided radiation therapy will enable us to treat more cancer tissue than normal tissue. In doing so, we could apply, in a single fraction, a huge dose to the tumor while avoiding side effects to normal tissues, he says.

The development of advanced imaging solutions for oncology therapy planning and delivery is a key focus area for Philips, says Gene Saragnese, CEO Imaging Systems at Philips Healthcare. Philips is already closely working together with Sunnybrook Health Sciences Centre in this field, and we welcome their expertise to the research consortium for MR guided radiotherapy. The members will jointly work on the design and implementation of the clinical studies with the objective of bringing image-guided oncology therapy to the next level, and ultimately creating the future of healthcare.

Read more:
Canada’s Sunnybrook Health Sciences Centre Joins Elekta and Philips Research Consortium on MRI-Guided Radiation Therapy

Washington, May 10 (ANI): A new study has found that dads' genome is more ready for fertilization than of mothers'.

Researchers from Huntsman Cancer Institute (HCI) at the University of Utah have discovered that while the genes provided by the father arrive at fertilization pre-programmed to the state needed by the embryo, the genes provided by the mother are in a different state and must be reprogrammed to match.

The findings have important implications for both developmental biology and cancer biology.

In the earliest stages, embryo cells have the potential to develop into any type of cell, a state called totipotency.

Later, this potency becomes restricted through a process called differentiation. As a result, as cells continue to differentiate, they give rise to only a subset of the possible cell types.

"In cancer, normal processes of cell differentiation and growth go wrong, and cells either become arrested at an early state of differentiation, or instead go backwards and are 'reprogrammed' to become more like early embryo cells," Bradley R. Cairns, co-author of the article and Senior Director of Basic Science at HCI said.

"By understanding how cells are normally programmed to the totipotent state, and how they develop from that totipotent state into specific cell types, we hope to better understand how cancer cells misregulate this process, and to use that knowledge to help us devise strategies to reverse this process," he said.

Cairns said that the work added another interesting finding.

"We found that the mother's genome takes care of that remodeling on its own, without using the father's genome as a template," he said.

Cairns' experiments showed that when the father's genetic contribution was removed, the mother's genome still remodeled itself to the correct state.

View post:
Male gene more ready at fertilization than female's

May 9, 2013 Researchers from the RIKEN Center for Integrative Medical Sciences have identified a gene that when mutated is responsible for a spectrum of disorders affecting the bones and connective tissue. This finding opens new avenues for research into a diagnosis and treatment for these until now incurable diseases.

The study is published today in the American Journal of Human Genetics.

Spondyloepimetaphyseal dysplasia with joint laxity, type I or SEMD-JL1 is a disorder of the skeleton resulting in short stature and spinal problems starting from birth, and worsening with age. The disease is also known as SEMD Beighton type.

In order to find the gene responsible for the disorder, and Dr Ikegawa and his team examined the entire coding sequence of the genome of 7 individuals suffering from SEMD-JL1 using next-generation sequencing technology.

The researchers found that the study subjects all had mutations that resulted in significant loss of function of the gene B3GALT6, known to be involved in the biosynthesis of an important component of connective tissue.

To the reseachers' surprise, mutations in B3GALT6 were also found in patients suffering from a disorder of the connective tissue called Ehlers-Danlos syndrome progeroid type.The researchers show that a deficiency in the B3GALT6 enzyme results in a spectrum of disorders affecting various tissues, including the skin, bones, cartilage, tendons and ligaments. Their results indicate that B3GALT6 is essential for the development and the maintenance of these tissues.

B3GALT6 is known to encode for an enzyme involved in the biosynthesis of the glucosaminoglycan (GAG) linker region.

"The GAG linker region is key for GAG biosynthesis and proteoglycan metabolism," explains Dr Ikegawa "and proteoglycans are important because they are a major component of the matrix of connective tissue in animals."

"Our findings show that mutations in B3GALT6 cause a spectrum of disorders that were previously thought to belong to different families of diseases - some were thought to be skeletal dysplasia and others connective tissue disorders," explain the authors.

"More clinical, genetic and biological studies are needed to understand the pathological mechanism of the diseases and the role of GAG metabolism and function," they conclude.

Read more here:
Gene identified, responsible for a spectrum of disorders affecting the bones and connective tissue

May 9, 2013 A novel gene associated with canine atopic dermatitis has been identified by a team of researchers led by professors Kerstin Lindblad-Toh, Uppsala university and ke Hedhammar, SLU, Sweden. The gene encodes a protein called plakophilin 2, which is crucial for the formation and proper functioning of the skin structure, suggesting an aberrant skin barrier as a potential risk factor for atopic dermatitis.

Details appear today in the open-access journal PLoS Genetics.

Atopic dermatitis (or eczema) is an inflammatory, relapsing non-contagious skin disease affecting about 10-30 percent of the human population. It is not only humans that suffer from the disease: about 3-10 percent of dogs are also affected. The skin of a patient with atopic dermatitis becomes easily irritated by various allergens such as certain types of food, pollens or house mites. Such irritation causes very strong itching which leads to scratching, redness and flaky skin that becomes vulnerable to bacterial and yeast infections.

To-date, despite many scientific efforts, little has been known about the genetics of the disease. In their study, researchers from Uppsala University, SLU and Broad Institute, compared DNA samples from a large group of German shepherd dogs affected by atopic dermatitis with DNA coming from healthy dogs to reveal the specific DNA segment associated with the disease.

"With the help of pet owners, we have managed to collect a unique set of DNA samples from sick and healthy dogs which allowed us to gain insight into atopic dermatitis genetics," said first author Katarina Tengvall, Uppsala University.

Purebred dogs such as German shepherds have been selected for specific physical features for several generations. Selection led to an inadvertent enrichment for disease-risk genes in certain breeds. Moreover, the resulting architecture of canine DNA makes it easier to pinpoint segments that carry these disease risk-genes. This helped the researchers to reveal the genetics of atopic dermatitis. They found a region associated with the atopic dermatitis containing the gene PKP-2, which encodes Plakophilin-2, a protein involved in the formation and maintaining of the proper skin structure.

"The finding that certain variants of the PKP-2 gene may increase the risk of developing the disease opens new possibilities in understanding the disease mechanism leading to atopic dermatitis," continues Katarina Tengvall.

These findings will not only lead to better understanding of the disease, which may lead to better treatment strategies long term. It also opens up the possibilities of development of a genetic test for the disease.

"Our study suggests that plakophilin-2 and an intact skin barrier is important to avoid atopic dermatitis," says senior author, Kerstin Lindblad-Toh, professor at Uppsala University and Director of SciLifeLab Uppsala. "Another gene involved in the skin barrier has recently been linked to human atopic dermatitis emphasizing the similarity between canine and human atopic dermatitis" continues Kerstin Lindblad-Toh.

The study was supported by the European Commission (FP7-LUPA, GA-201370) and the Swedish Research Council Formas. KT was supported by the Uppsala University, MK was supported by the Swedish Foundation for Strategic Research (SSF) grant and C and KLT were supported by independent EURYI-Awards. FF was supported by the Swedish Institute Scholarship.

See original here:
Gene associated with eczema in dogs identified

By Amy Norton HealthDay Reporter

WEDNESDAY, May 8 (HealthDay News) -- Mutations in a gene involved in bone development appear to cause certain severe forms of bone loss, a finding that could lead to new therapies for the common bone-thinning disorder osteoporosis, researchers report.

The mutations were found in a Swedish family with 10 members affected by a severe, early onset form of osteoporosis, as well as a Hmong family from Laos in which two sisters suffered from osteogenesis imperfecta.

Osteogenesis imperfecta, which is also known as brittle bone disease, affects six to seven out of every 100,000 people worldwide. The disease causes the bones to break easily, often from little or no trauma. There are four main forms, the most severe of which is fatal before or soon after birth.

The most common -- and mildest -- form is Type 1, in which most of a child's bone fractures happen before puberty. Some other problems, such as weak muscles and brittle teeth, are also possible.

Researchers have long known that about 90 percent of osteogenesis imperfecta cases are caused by a single mutation in one of two genes involved in making collagen, a fibrous protein in bone, skin and connective tissue.

It is only in the past decade, though, that the mystery behind the other 10 percent has become clearer, said Dr. Francis Glorieux, chairman of the Osteogenesis Imperfecta Foundation's medical advisory council.

The latest findings, published in the May 9 issue of the New England Journal of Medicine, underscore the role of a gene family known as WNT, said Glorieux, who was not involved in the research.

WNT genes make proteins called ligands, which means they latch onto receptors on the surface of body cells. Scientists have known that WNT is important in bone development and the upkeep of bone mass.

"But we haven't known which protein is key, which WNT ligand is actually doing the work. This study addresses that," said lead researcher Dr. Brendan Lee, a professor of molecular and human genetics at Baylor College of Medicine in Houston.

Original post:
Gene Discoveries Give Hope Against 'Brittle Bone' Disease

Genetic Engineering PSA Final
I don #39;t own any of the material, sound, videos, music, etc. This video was made for a school project so there is no other purpose than academic purposes.

By: Melissa Salinas

Go here to read the rest:
Genetic Engineering PSA Final - Video

Public release date: 9-May-2013 [ | E-mail | Share ]

Contact: Vicki Cohn vcohn@liebertpub.com 914-740-2100 Mary Ann Liebert, Inc./Genetic Engineering News

New Rochelle, NY, May 9, 2013Insomnia and other sleep disturbances are common among perimenopausal and postmenopausal women and may increase their risk of coronary heart disease (CHD) and cardiovascular disease (CVD). Evidence that a combination of altered sleep duration and insomnia among women ages 50-79 doubled their risk of both CHD and CVD over a period of more than 10 years is presented in an article in Journal of Women's Health, a peer-reviewed publication from Mary Ann Liebert, Inc., publishers. The article is available free on the Journal of Women's Health website at http://www.liebertpub.com/jwh.

In "Sleep Duration, Insomnia, and Coronary Heart Disease among Postmenopausal Women in the Women's Health Initiative," Megan Sands-Lincoln, PhD, MPH and a team of researchers from leading medical institutions across the U.S. gathered self-reported data on sleep duration and insomnia in 86,329 women 50-79 years of age. Shorter (<5 hours) and longer (>10 hours) sleep duration and insomnia were associated with higher incidence of CHD and CVD over 10.3 years, and when considered together, the interaction risk of insomnia and sleep duration was significant.

"This is the first study to investigate interactions of sleep duration with insomnia in relation to increased risk of CHD and CVD in postmenopausal women," says Susan G. Kornstein, MD, Editor-in-Chief of Journal of Women's Health, Executive Director of the Virginia Commonwealth University Institute for Women's Health, Richmond, VA, and President of the Academy of Women's Health.

###

About the Journal

Journal of Women's Health, published monthly, is a core multidisciplinary journal dedicated to the diseases and conditions that hold greater risk for or are more prevalent among women, as well as diseases that present differently in women. The Journal covers the latest advances and clinical applications of new diagnostic procedures and therapeutic protocols for the prevention and management of women's healthcare issues. Complete tables of content and a sample issue may be viewed on the Journal of Women's Health website at http://www.liebertpub.com/jwh. Journal of Women's Health is the Official Journal of the Academy of Women's Health and the Society for Women's Health Research.

About the Academy

Academy of Women's Health is an interdisciplinary, international association of physicians, nurses, and other health professionals who work across the broad field of women's health, providing its members with up-to-date advances and options in clinical care that will enable the best outcomes for their women patients. The Academy's focus includes the dissemination of translational research and evidence-based practices for disease prevention, diagnosis, and treatment of women across the lifespan.

Excerpt from:
Do insomnia and disrupted sleep during menopause increase a woman's risk of heart disease?

To catch Antarctic toothfish, you must bait your hook with Peruvian squid and cast it into the depths of the Ross Sea. This is what a team of Ukrainians did on a fishing trip near Antarctica. But sometimes, Mother Nature trips you up. Sometimes, you catch a hopbeard plunderfish.

In 2009-2010, Ukrainian mariners happened to pull up three fish that looked unfamiliar. Further analysis found that they were a previously undiscovered species, dubbed the hopbeard plunderfish and described in a study published online April 29 in the journal ZooKeys. The fish bear the scientific name Pogonophryne neyelovi.

The strange-looking denizens of the deep have brownish-splotched bodies and are shaped somewhat like tadpoles, especially when young, according to the study. They have sharp dorsal fins that extend along the top of their bodies and strange "barbels," which resemble dirty Q-tips, that extend from their chins.

The longest of the three specimens measured 14 inches (35.5 centimeters). And they really like to live in the deep they were pulled from depths of up to 4,560 feet (1,390 meters).

The fish have large livers, which fill up to 35 percent of their abdomen. Whether or not that means these sea creatures could drink like, well, fish, is unknown.

If you're fond of the hopbeard, just wait until you meet its cousins. The genus Pogonophryne, also known as the short-barbeled plunderfish, has a total of 22 species. These fish also live in the frigid waters surrounding Antarctica. Some of them live in the Ross Sea, like the hopbeard, which is found offshore of Antarctica's Ross Ice Shelf.

Currently, next to nothing is known about their behavior, diet or what they do down there in the depths.

Email Douglas Main or follow him @Douglas_Main. Follow us @OAPlanet, Facebook or Google+. Original article on LiveScience's OurAmazingPlanet.

Copyright 2013 LiveScience, a TechMediaNetwork company. All rights reserved. This material may not be published, broadcast, rewritten or redistributed.

Excerpt from:
New Deep-Sea Fish Species Found in Antarctica

SAN DIEGO, May 9, 2013 /PRNewswire/ --Sequenom, Inc. (SQNM), a life sciences company providing innovative genetic analysis solutions, today reported revenue of $38.5 million for the first quarter of 2013, an increase of 158% compared to revenue of $14.9 million for the first quarter of 2012. First quarter 2013 revenues from the Sequenom Center for Molecular Medicine (Sequenom CMM) diagnostics services operating segment grew more than 38% as compared to the fourth quarter of 2012.

"The volume of 35,000 MaterniT21 PLUS tests accessioned in the first quarter shows that Sequenom CMM continued to take advantage of its first mover position in the non-invasive prenatal diagnostic (NIPT) market by increasing its penetration of the NIPT market and maintaining its dominant market share. The recent announcement that Sequenom CMM had accessioned over 100,000 MaterniT21 PLUS test samples since the test was launched in October of 2011 is further evidence of the remarkable success of this testing service," said Harry F. Hixson, Jr., Ph.D., Chairman and CEO of Sequenom. "Furthermore, we are making progress in our negotiations within the payor community, with more than 70 million patients now under coverage who have access to the MaterniT21 PLUS test."

Revenues from the Sequenom CMM diagnostics services operating segment grew to more than $29 million in the first quarter of 2013, up from $4.8 million in the prior year period. As of the first quarter 2013, diagnostic revenue accounted for more than 75% of total revenue, up from 63% in the fourth quarter of 2012.

Revenues from the Sequenom CMM diagnostics services operating segment are recorded primarily on a cash basis. Approximately 35% of diagnostic revenue reported for the first quarter 2013 is attributable to tests performed in the same period. Approximately 65% of the diagnostic revenue reported in the first quarter 2013 is related to payment collected on tests performed in prior periods. First quarter 2013 revenues from the genetic analysis operating segment decreased 7% from the same period in 2012, due to a softening in consumables orders, partially due to timing.

Total cost of revenues increased to $24.5 million for the first quarter of 2013, compared to $10.3 million for the prior year period. Cost of revenues increased primarily due to the significant increase in Sequenom CMM's test volumes and costs to support increased testing capacity, as total tests accessioned increased 250% to more than 44,500 patient samples during the first quarter of 2013. Approximately 35,000 of those patient samples tested during the first quarter were MaterniT21 PLUS test samples, compared to approximately 25,000 in the fourth quarter of 2012, growing 40% sequentially.

Overall gross margin for the first quarter of 2013 was 36% as compared to gross margin of 31% for the first quarter of 2012. This improvement is attributable primarily to the positive contribution from the Sequenom CMM diagnostic services business resulting from higher cash collections during the quarter and improved efficiencies in processing patient samples. Gross margin for the Sequenom CMM diagnostics services business in the first quarter of 2013 was approximately 28%, as compared to a negative gross margin in the first quarter of 2012. Gross margin for the genetic analysis business for the first quarter of 2013 was 63% compared to 66% for the prior year period.

Total operating expenses for the first quarter of 2013 were $41.0 million, as compared to total operating expenses of $28.9 million for the first quarter of 2012, down sequentially from total operating expenses of $42.0 million for the fourth quarter of 2012. Selling and marketing expenses increased to $13.7 million for the first quarter of 2013 from $9.7 million year-over-year, resulting primarily from higher labor costs associated with the expansion of the Sequenom CMM sales force and increased headcount to support commercial operations. Research and development expenses increased to $13.8 million for the first quarter of 2013, as compared to $11.8 million in the first quarter of 2012, related primarily to increased labor and supplies and costs relative to the expansion into the Sequenom CMM North Carolina facilities.

General and administrative expenses for the first quarter of 2013 were $13.5 million, as compared to $7.4 million for the first quarter of 2012, primarily due to increased legal expenses associated with patent litigation, increased collection costs due to the increase in diagnostics revenue and increased headcount to support the Company's operations. Total stock-based compensation expense was $3.1 million for the first quarter of 2013, an increase from $2.9 million in stock-based compensation recorded for the first quarter of 2012.

Net loss for the first quarter of 2013 was $29.4 million, or $0.26 per share, as compared to net loss of $24.4 million, or $0.22 per share, for the same period in 2012. Net cash used in operating activities was $19.7 million for the first quarter of 2013, compared to $23.3 million in the same period in the prior year. The Company also used cash for capital investments of $4.1 million and debt repayments of $1.8 million during the first quarter of 2013. As of March 31, 2013, total cash, cash equivalents, and marketable securities were $151.1 million.

"We are pleased to see sequential improvements in volume, revenue and margin during the quarter, an indication of steady growth and sustained momentum in 2013," said Paul V. Maier, Sequenom's CFO. "As we complete the process of moving our billing and collections processes in-house, we anticipate even greater control in monitoring our payments from payors and improved workflows that will help us improve our collection cycle and reimbursement."

Continued here:
Sequenom, Inc. Reports Financial Results For The First Quarter Of 2013

Scientists find mutation that results in red or purple marks Breakthrough described as 'complete game changer' Condition could now be prevented in children

By Nick Mcdermott

PUBLISHED: 01:55 EST, 9 May 2013 | UPDATED: 03:48 EST, 9 May 2013

Genetics: Birthmarks may become a thing of the past thanks to the efforts of researchers in the U.S. File picture

Unsightly birthmarks that affect thousands of newborns each year could soon be eradicated.

Scientists have found a genetic mutation which is responsible for port wine stain marks, and claim the discovery is a 'complete game changer' which they hope will lead to new preventative treatments.

One in every 300 children born in Britain has the condition which results in red or purple marks on the body, most commonly on the neck or face.

They are caused by the abnormal development of blood vessels in the skin, and the birthmark may become thicker, darken and develop a raised appearance in later years.

A research team in the U.S. has now proved the condition occurs because of a gene mutation, which occurs after conception.

Although laser treatment can lighten their appearance, the birthmarks are not curable. The genetic mutation discovered by researchers at Kennedy Krieger Institute in Baltimore is also responsible for Sturge-Weber syndrome (SWS), a rare disorder that affects the eyes and brain, and is associated to port wine stain.

Read the original post:
Genetic breakthrough means birthmarks could soon be eradicated

Hereford Genetics; The next decade...where are you going? - Dr David Johnston
Animal Genetics Breeding Unit (AGBU) Principal Scientist Dr David Johnston speaks about Hereford Genetics; The next decade...where are you going? at the He...

By: HerefordsAustralia

Here is the original post:
Hereford Genetics; The next decade...where are you going? - Dr David Johnston - Video

Immunology Lecture 11 Part 5 Genetics of Immunoglobulin Diversity
Immunoglobulins are important part of immune systems. These molecules are instrumental for defending against viruses, bacteria, and helminths etc. These mole...

By: Mobeen Syed

Continue reading here:
Immunology Lecture 11 Part 5 Genetics of Immunoglobulin Diversity - Video

Skittles - Genetics
It #39;s Bring-Your-Infant-To-Work Day! Directed By: Allison Collins Written By: Henry Held Edited By: Colton Moyer.

By: VanMoyerVids

Read the original post:
Skittles - Genetics - Video

Genetics 004
Back cross, test cross, law of segregation, dihybrid cross grade x.

By: Sandeep Changlani

Continue reading here:
Genetics 004 - Video

Alex Jones David Icke - GMOs, Human Genetics and Pedophilia
British author David Icke has written 20 books and traveled to over 55 countries since 1990. His books reveal how a hidden hand is behind world-changing even...

By: DismantleTheMatrix

See more here:
Alex Jones

Minerals, Genetics and Q A
More info on minerals. More info on genetics.

By: bios3training

Excerpt from:
Minerals, Genetics and Q

DNA Genetics Exodus Kush Marijuana Clones
Two leggy DNA Genetics Exodus Kush marijuana clones are just entering the first week of flowering. These plants are known to stretch substantially during the...

By: Matt Mernagh

More:
DNA Genetics Exodus Kush Marijuana Clones - Video

11.5 Population Genetics

By: Barbra Bedwell

Continue reading here:
11.5 Population Genetics - Video

The Genetics Course Pack
Washington University School of Medicine (Class of 2016) 1st Year Class Show.

By: WUSM2016

Continue reading here:
The Genetics Course Pack - Video

UK Biobank genetics
Dr Cathie Sudlow, Chief Scientist at UK Biobank, talks about the work of UK Biobank in genetics.

By: Andrew Trehearne

Read more:
UK Biobank